Newer calcimimetic agents include etelcalcetide, which achieves a 10% greater reduction in PTH levels compared to cinacalcet but does not improve gastrointestinal tolerance and carries a higher risk of hypocalcemia. Here, PTH is linked to Hypocalcemia.